Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CTDSPL2 pseudogene 1 is a pseudogene of the CTD small phosphatase like 2 (CTDSPL2) gene. Pseudogenes are generally considered non-functional DNA segments resulting from gene duplication or retrotransposition; most do not encode functional proteins or have direct therapeutic relevance[3]. There is no evidence that CTDSPL2P1 is transcribed or translated into a functional product, nor that it serves as a clinically relevant receptor, enzyme, transporter, or other active drug target. Functional studies and therapeutic research primarily concern the parent gene, CTDSPL2, a nuclear serine/threonine phosphatase involved in transcriptional regulation and cell cycle control, with emerging roles in cancer biology[1][2]. CTDSPL2 pseudogene 1 (CTDSPL2P1) is not a recognized therapeutic target; it is a pseudogene lacking confirmed molecular or therapeutic relevance[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CTDSPL2 pseudogene 1 (CTDSPL2P1).